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palifermin on the incidence of mucositis in children
following AHSCT has never been studied. In this retrospec-
tive study, we compared the incidence of mucositis and
supportive care required in childrenwho received palifermin
vs. controls (no palifermin) during non-TBI AHSCT. Mucositis
was graded as per WHO criteria. The continuous variables
were summarized by the mean and standard deviation; the
categorical variables were summarized by percentage. The
palifermin vs. control group were compared by two-sided t-
test for continuous measurements and by Chi-square test for
categorical measurements. From 2005-2011, 58 patients
received myeloablative AHSCT, of which n¼25 were in the
palifermin group and n¼33 were in the control group.
Demographic characteristics are presented in Table.
Comparing palifermin vs. the control group: the average time
for neutrophil engraftment was 12.163.21 days vs. 11.5
1.68 (P¼.127), the incidence of grade I and III-IVmucositis
was 80% vs. 90.9%, and 20% (P¼ .02) vs. 42.4% (P¼.07), the
number of days with fever were 4.923.49 vs. 7.094.86
(P¼.063), the number of days patients received PCA were
8.808.39 vs. 8.308.54 (P¼.826), and the number of days
patients were on TPN were 13.5211.32 vs. 11.559.63
(P¼.484), respectively. The incidence of blood stream and
Clostridium difﬁcile infection was 36% vs. 27.3% (P¼.4) and
24% vs. 18.2% (P¼.5), respectively. The average length of
hospital stay 31.447.42 vs. 28.6110.38 (P¼.252) was not
statistically different between the palifermin and control
groups. In summary, we were unable to demonstrate that
there was a statistical difference with incidence of mucositis
and other supportive care needs or a decrease in hospital
stay in the palifermin group. In children receiving AHSCT,
palifermin should only be used in the setting of a large
prospective study.Variable Control group
(No Palifermin,
n¼33) Mean (SD)
Palifermin group
(n¼25)Mean (SD)
P-value
Age 6.85 (5.49) 7.96 (6.19) .473
Gender:
Male 20 (60.6%) 14 (56%) .724
Female 13 (39.4%) 11 (44%)
Weight 30.62 (27.08) 35.02 (25.95) .535
BSA 0.98 (0.55) 1.05 (0.51) .580
Brain Tumor 15 (45.5%) 3 (12%) .024
Solid Tumor 11 (33.3%) 14 (56%)
Lymphoma 7 (21.2%) 8 (32%)
Disease Status .671
CR/PR 29 (87.9%) 21 (84.0%)
SD/PD 4 (16%) 4 (12.1%)
Prior Radiation: .120
Yes 3 (9.1%) 6 (24%)
No 30 (90.9%) 19 (76%)
HSV serostatus: .330
Positive 25 (75.8%) 16 (64%)
Negative 8 (24.2%) 9 (36%)
Creatinine clearance 118.1 (42.55) 134.8 (49.31) .176TRANSPLANT PHARMACY ORAL
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Background: The use of ﬁlgrastimwith or without plerixafor
has been shown to be an effective modality for the mobili-
zation of peripheral blood stem cells. However, questions
remain as to the CD34+ count that would best predict for
efﬁcient collection. We developed a ﬁlgrastim-based mobi-
lization algorithm with a predetermined decision point for
the inclusion of plerixafor and a CD34+ count of 20 cells/uL as
the trigger for collection. The purpose of our evaluation was
to determine the efﬁcacy of this algorithm, as well as the
impact on plerixafor use, in patients undergoing mobiliza-
tion with ﬁlgrastim prior to autologous hematopoietic stem
cell transplant (HSCT).
Methods: Patients received ﬁlgrastim 10 mcg/kg SC once
daily for 4 days. If the day 5 CD34+ count was > 20/ul,
apheresis was started and ﬁlgrastim was continued until the
collection goal was met. If the day 5 CD34+ count was <10,
plerixafor was started, and if the day 5 CD34+ count was 10-
20, ﬁlgrastim was continued for 1 day with plerixafor added
if the day 6 CD34+ count remained <20/uL. Mobilization
efforts were stopped if the blood CD34+ count remained <
10. The CD34+ cell collection goal was 4 x 106 cells/kg, with
a minimum requirement of 2 x 106 to proceed to HSCT.
Results: To date, 21 patients (18 multiple myeloma and 3
other) have been treated. Fifteen of 18 myeloma patients
received prior lenalidomide therapy. Eleven of the 21
patients were successfully mobilized using ﬁlgrastim alone.
Nine patients who had inadequate CD34+ mobilization with
ﬁlgrastim alone responded to the addition of plerixafor.
Patients requiring plerixafor received an average of 1.56
doses. One patient with non-Hodgkin's lymphoma had no
response to ﬁlgrastim and therefore mobilization attempts
were halted. Seventeen of the 21 patients have successfully
proceeded to transplant, with 3 of the remaining 4 expected
to be admitted for HSCT within the next month. Patients
collected in an average of 1.7 apheresis sessions and collected
an average of 5.15 x 106 CD34+ cells/kg.
Conclusion: We demonstrate here a successful and cost-
effective algorithm-based approach to mobilization,
including a predetermined strategy to include plerixafor for
poormobilizers. By using a decision point for the inclusion or
exclusion of plerixafor, we avoided use of the agent in
patients unlikely to need it for successful collection.122
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Background: Chemotherapy plus GCSF has been an effective
modality for the mobilization of peripheral blood stem cells.
However, the optimal drug, dose, and schedule have not
Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177S176been established. Additionally, the role of plerixafor in che-
momobilization protocols has not been clearly described. We
developed a chemomobilization algorithm using a 2-day
infusion of etoposide at 300 mg/m2 followed by GCSF. The
algorithm included a predetermined decision point for the
addition of plerixafor for poormobilizers. The purpose of this
study is to prospectively evaluate the safety and efﬁcacy of
this algorithm in patients undergoing chemomobilization
ahead of autologous HSCT.
Methods: Patients underwent chemomobilization using
etoposide at a dose of 300 mg/m2 daily for 2 days, followed
by ﬁlgrastim 10 mcg/kg starting on day 3. At day 12, patients
began WBC screening, and once the WBC count rose to > 2 x
109/L, CD34+ screening began. If the CD34+ count was >20/
uL, patients proceeded to collection. If the CD34+ count was
<20/uL, plerixafor was added. Patients who required pler-
ixafor to reach a CD34+count >20/uL remained on plerixafor
daily until their collection goal was met. The CD34+ stem cell
collection goal was 4 x 106 cells/kg, with a minimum
requirement of 2 x 106 cells/kg to proceed to HSCT.
Results: To date, 21 patients (14 lymphoma, 5 multiple
myeloma, and 2 other) have been treated with our algorithm.
Four of the ﬁve patients withmultiple myeloma had received
> 6 cycles of lenalidomide. Of the 21 patients, 18 were
successfully mobilized using etoposide plus ﬁlgrastim alone.
The 3 patients who had inadequate CD34+ mobilizationwith
etoposide plus ﬁlgrastim all responded to the addition of
plerixafor. To date, 16 of the 21 patients have successfully
been transplanted, with the remaining 5 expected to
complete SCT within the next month. Patients collected with
an average of 1.4 apheresis sessions and collected an average
of 6.23 x 106 CD34+ cells/kg. Four patients (19%) were
hospitalized due to febrile neutropenia during the course of
mobilization.
Conclusion: We demonstrated a successful algorithm-based
approach to chemomobilization that included a pre-
determined strategy to include plerixafor for poor mobi-
lizers.123
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Background: MMF is hepatically metabolized to mycophe-
nolic acid (MPA) glucuronide and reconverted to an active
MPA by colonic bacteria (Shaw et al, Clin Biochem 2001).
MPA area under the curve and steady state concentration
(Css) predict acute rejection in solid organ transplant. MMF
at 900 mg/m2 q6h results in (MPA) Css concentrations
between 4.73 (2.22) to 6.54 (3.55) mcg/mL in pediatric
recipients post-AlloSCT (Bhatia/Militano/Cairo, BBMT 2010).
Objective: To determine safety/efﬁcacy of MMF at 900 mg/
m2/dose q8h in combination with tacrolimus in pediatric
AlloSCT recipients.
Methods: GVHD prophylaxis included tacrolimus 0.03-0.04
mg/kg/day IVCI on Day -1 or 1st day of conditioning(target range 10-20 ng/mL) and MMF 900 mg/m2 (max 1.5
g/dose) IV/PO q8h starting on Day +1. MPA trough
concentrations were obtained if toxicity or acute GVHD
(aGVHD) was suspected. AGVHD, chronic GVHD (cGVHD)
and overall survival (OS) were determined by Kaplan-
Meier method.
Results: 15 pts: mean age 9.1 yrs (range 0.8-17.2); M:F 13:2;
7 pts non-malignant & 8 with malignant disease; donor
source: 4 related BM, 5 MUD, 5 UCB, 1 haploSCT; condi-
tioning: 8 myeloablative and 7 reduced intensity. Median
time to myeloid and platelet engraftment was 17 and 29
days, respectively. Probability of Grade II-IV aGVHD and
limited + extensive cGVHD was 35.3% (CI95:5.7-68.5) and 0%,
respectively. Probability of 1-year OS was 78.7% (CI95: 38.0-
94.2). Four pts had MPA trough levels prior to day +30 (mean
trough 1.22 mcg/mL; range <0.5e2). Eight pts had 15 MPA
trough concentrations reported Day +30 to Day +100 (mean
trough 4.2 mcg/mL; range < 0.5e7.9). Four of 8 (50%)
patients had MPA trough levels above the recommended
maximum of 3.5 mcg/mL during Day +30 to +100 post-
transplant period.
Conclusion: MMF at 900 mg/m2 q8h in combination with
tacrolimus appears effective for prevention of aGVHD and
cGVHD in the pediatric AlloSCT recipients. MMF dosing
and pharmacokinetics in the later post-SCT period (Day
+30 to Day +100) deserve further attention due to
increased potential for high MPA trough concentrations.
The potential difference in MPA trough concentration
between early (<Day +30) or late post-SCT period, could
be due to improved mucosal healing following condi-
tioning that leads to improved drug absorption and
enterohepatic recirculation. Based on these results, we
recommend MMF dose reduction and monitoring MPA
trough concentrations in the late post-AlloSCT period to
avoid potential toxicity.124
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Background: Invasive fungal infections are a signiﬁcant
cause of morbidity and mortality in recipients of hemato-
poietic cell transplantation (HCT), warranting antifungal
prophylaxis as a standard of care. A number of options are
available for prophylaxis, but none have been found to be
ideal. Due to its broad spectrum of activity and multiple
dosage forms, voriconazole remains one of the commonly
used agents in this setting. It's well known that there is
wide inter and intra-patient variability in voriconazole
